These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 30977947)
1. Complete healing of basal cell carcinoma under bendamustine and brentuximab vedotin therapy in a patient with cutaneous lymphoma. Baykal C; Kutlay A; Buyukbabani N Dermatol Ther; 2019 Jul; 32(4):e12934. PubMed ID: 30977947 [No Abstract] [Full Text] [Related]
2. Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas. Dumont M; Ram-Wolff C; Roelens M; Brice P; Peffault de Latour R; Battistella M; Madelaine I; Delyon J; Herms F; Bouaziz JD; Moins-Teisserenc H; Lebbé C; Bagot M; de Masson A Br J Dermatol; 2019 Dec; 181(6):1315-1317. PubMed ID: 31206589 [No Abstract] [Full Text] [Related]
3. Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine. Poon LM; Kwong YL Ann Hematol; 2016 Apr; 95(5):847-9. PubMed ID: 26931114 [No Abstract] [Full Text] [Related]
4. RF - Brentuximab as Treatment for CD30 Morgado-Carrasco D; Combalia A; Estrach Panella T Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669 [No Abstract] [Full Text] [Related]
5. [Long-term administration of brentuximab vedotin in a patient with primary cutaneous anaplastic large cell lymphoma with peripheral blood involvement with leukemic change]. Kumekawa H; Mizuchi D; Iiyama M Rinsho Ketsueki; 2018; 59(2):187-190. PubMed ID: 29515072 [TBL] [Abstract][Full Text] [Related]
6. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556 [TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of the combination of systemic gemcitabine and intralesional brentuximab vedotin in tumor-stage mycosis fungoides. Torre-Castro J; Recio-Monescillo M; Castillo Bazan E; Díaz de la Pinta J; Rodríguez Pinilla M; Requena L; Córdoba R Int J Dermatol; 2024 Jun; 63(6):828-830. PubMed ID: 38419393 [No Abstract] [Full Text] [Related]
8. Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin. Desai A; Telang GH; Olszewski AJ Ann Hematol; 2013 Apr; 92(4):567-8. PubMed ID: 23086510 [No Abstract] [Full Text] [Related]
9. Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin. Sasapu A; Dunn ALJ; Gardner J; Wong HK BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34290015 [TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma. Wolf S; Goiriz R; Dhairyawan R; Paige D; Rizvi H; Haroon A; Montoto S Clin Exp Dermatol; 2019 Jul; 44(5):562-564. PubMed ID: 30430604 [No Abstract] [Full Text] [Related]
11. Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis. Sheehy O; Catherwood M; Pettengell R; Morris TC Leuk Lymphoma; 2009 Aug; 50(8):1389-91. PubMed ID: 19544141 [No Abstract] [Full Text] [Related]
12. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. Kalac M; Lue JK; Lichtenstein E; Turenne I; Rojas C; Amengual JE; Sawas A; Deng C; Mapara MY; Connors JM; Kuruvilla J; O'Connor OA Br J Haematol; 2018 Mar; 180(5):757-760. PubMed ID: 27984643 [No Abstract] [Full Text] [Related]
13. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin. Howell M; Gibb A; Radford J; Linton K Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404 [No Abstract] [Full Text] [Related]
14. Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin. Şahin M; Miskioğlu M; İnanır I; Akar H; Neşe N; Temiz P; Aydoğdu İ Turk J Haematol; 2021 Feb; 38(1):85-87. PubMed ID: 33504137 [No Abstract] [Full Text] [Related]
15. Sarcomatoid Variant of Primary Cutaneous Anaplastic Large Cell Lymphoma. Natsuaki Y; Muto I; Kawamura M; Saruta H; Teye K; Ohshima K; Nakama T; Ohata C Am J Dermatopathol; 2019 Dec; 41(12):e164-e167. PubMed ID: 31268929 [TBL] [Abstract][Full Text] [Related]
16. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247 [TBL] [Abstract][Full Text] [Related]